Program
Embibatinib
Also written as “HS-10382”, “MK-4208” and “TERN-701”.
In Hansoh Pharmaceutical Group’s pipeline, BCR-ABL (STAMP)
. Its studies are mostly in Leukemia, Myelogenous, Chronic, BCR-ABL Positive · Leukemia, Myeloid, Chronic-Phase, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Hansoh Pharmaceutical Groupits history only | 44 open or running | phase 3since Oct 12, 2026 | May 6, 2022 | Feb 2027phase 1 · NCT07933224 |
| Merck | 31 open or running | phase 2since Nov 8, 2023 | Nov 8, 2023 | Nov 30, 2029phase 2 · NCT06163430 |
- Named in Hansoh Pharmaceutical Group’s own pipeline as
HS-10382 (STAMP, Terns's TERN-701)
, phase 1, as of Aug 26, 2026 (source).
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Merck only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Nov 8, 2023First study: phase 2 study in Leukemia, Myelogenous, Chronic, BCR-ABL PositiveFirst studyNCT06163430 · 330 planned · United States, Australia, France and more
- Jan 29, 2026Named embibatinibINNProposed as its International Nonproprietary Name in WHO's List 134 · before, HS-10382, MK-4208, TERN-701
- Sep 18, 20262 phase 1 studies in HealthyNCT07839000, NCT07838987
Ahead
- Nov 30, 2029Primary completion: phase 2 study in Leukemia, Myelogenous, Chronic, BCR-ABL PositiveNCT06163430
TargetBeta
“BCR-ABL (STAMP)”the company's pipeline, read by Claude · source
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| imatinibrule | Novartis | phase 4 | 70 |
| nilotinibrule | Novartis | phase 4 | 57 |
| asciminibrule | Novartis | phase 4 | 16 |
| olverembatinibrule | Ascentage Pharma Group International | phase 3 | 10 |
| TQB3911 | Sino Biopharmaceutical | phase 1 | 1 |
Studies
All 3 Merck leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07839000Healthy · United States | 1 | Completed | Apr 3, 2026 | 8 |
| NCT07838987Healthy · United States | 1 | Completed | Jun 30, 2026 | 196 |
| NCT06163430Leukemia, Myelogenous, Chronic, BCR-ABL Positive · United States, Australia, France and more | 2 | Recruiting | Nov 30, 2029 | 330 |
How it is read
Names in the registry
- “HS-10382”, 2 entries
- “Embibatinib”, 1 entry
- “MK-4208”, 1 entry
- “TERN-701”, 1 entry
- “HS-10382+Flumatinib”, 1 entry
Conditions, from the studies’ own filings
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive, 3 studies
- Leukemia, Myeloid, Chronic-Phase, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.